Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies

Chang-Hua Zhang,Bu-Gao Zhou,Jun-Qing Sheng,Yang Chen,Ying-Qian Cao,Chen Chen,Chang-hua Zhang,Bu-gao Zhou,Jun-qing Sheng,Ying-qian Cao
DOI: https://doi.org/10.1016/j.phrs.2020.104984
IF: 10.334
2020-09-01
Pharmacological Research
Abstract:<p>The prevalence of nonalcoholic fatty liver disease (NAFLD) in the general population is estimated at 25%, and there is currently no effective treatment of NAFLD. Although insulin resistance (IR) is not the only factor causing the pathogenesis of NAFLD, hepatic IR has a cause-effective relationship with NAFLD. Recovering insulin sensitivity is a potential therapeutic strategy to treat NAFLD. This review highlights the molecular mechanisms of hepatic IR in the development of NAFLD. Available data on potential drugs including glucagon-like peptide 1 receptor (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR-γ/α/δ) agonists, farnesoid X receptor (FXR) agonists, etc. are carefully discussed.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?